Skip to content

Evaluation of the Efficacy of Helicobacter pylori Eradication Therapy in Autoimmune Gastritis with Coexisting Infection

Evaluation of the Efficacy of Helicobacter pylori Eradication Therapy in Autoimmune Gastritis with Coexisting Infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115025
Enrollment
Unknown
Registered
2025-12-22
Start date
2025-12-31
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Gastritis

Interventions

immediate H. pylori eradication group:Research participants randomized to the immediate H. pylori eradication group will receive a standard course of bismuth-containing quadruple therapy promptly afte
Delayed H. pylori Eradication Group:Participants in this group will first enter a 12-month standard clinical follow-up period upon enrollment, during which symptomatic/supportive care is permitted. Th

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Aged 18 to 75 years, regardless of gender. Meeting the diagnostic criteria for both Autoimmune Gastritis (AIG) and H. pylori infection. Provision of written informed consent.

Exclusion criteria

Exclusion criteria: 1. History of prior H. pylori eradication therapy, or current use of antibiotics or proton pump inhibitors (PPIs) within the past 4 weeks. 2. Presence of severe dysplasia, intraepithelial neoplasia, gastric cancer, or gastric neuroendocrine tumors observed during the screening endoscopy. 3. History of gastric cancer or major gastrectomy. 4. Requirement for long-term, continuous use of medications including proton pump inhibitors (PPIs), non-steroidal anti-inflammatory drugs (NSAIDs), or corticosteroids. This also includes patients with other systemic autoimmune diseases (e.g., systemic lupus erythematosus, myasthenia gravis) whose condition may confound the study outcomes. 5. Severe hepatic or renal dysfunction, cardiac insufficiency, or active malignancy. 6. Known allergy or hypersensitivity to any component of the study medications. 7. Pregnant or breastfeeding women. 8. Inability to comply with the scheduled follow-up procedures.

Design outcomes

Primary

MeasureTime frame
Histological Improvement Rate;Disease Progression Rate;

Secondary

MeasureTime frame
Serum Autoantibody Levels;Gastric Acid Secretory Function;Anemia and Nutritional Indices;Clinical Symptoms and Quality of Life;H. pylori Eradication Rate;

Countries

China

Contacts

Public ContactZhu Wang

West China Hospital of Sichuan University

wangzhu@wchscu.cn+86 189 8060 2897

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026